All In Biotech

Drug Trial Radar · NCT04562870

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis

Last checked: Nov 21, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Mar 17, 2021

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Karyopharm Therapeutics IncIndustry
Sponsor type
Industry
First posted
Sep 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.

Conditions

  • Myelofibrosis

Interventions

  • SelinexorDrug

    Unit Dose Strength: 20 mg; Dose Formulation: Tablet; Dosage Level: 60 or 80 mg, QW; Route of Administration: Oral

  • Physician's Choice TreatmentOther

    Physician's choice treatment may include ruxolitinib retreatment, fedratinib, chemotherapy (e.g., hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulatory agent, androgen, interferon (all as per clinical practice) and may include supportive care only with no MF treatment; no investigational therapies are allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Spleen Volume Reduction of Greater Than or Equal to (≥) 35 Percent (%) (SVR35)Time frame: From Baseline up to Week 24

Locations

21 sites in 7 countries. Site status is shown where the registry gives one.

  • The Oncology Institute of Hope and Innovation

    Pasadena, California

  • Rocky Mountain Cancer Centers, LLP

    Aurora, Colorado

  • Illinois Cancer Specialist

    Niles, Illinois

  • Texas Oncology - Northeast Texas

    Tyler, Texas

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Suzhou University -The First Affiliated Hospital

    Suzhou, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Sir Run Run Shaw Hospital - Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Centre Hospitalier Universitaire d'Angers (CHU Angers)

    Angers, France

  • Institut de Cancéro-Hématologie

    Brest, Brittany Region, France

  • University General Hospital "ATTIKON"

    Athens, Attica, Greece

  • Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica

    Florence, Italy

  • Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti

    Latina, Italy

  • University of Perugia Department of Medicine Hematology Section

    Perugia, Italy

  • Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi

    Varese, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS

    Meldola, Forlì-Cesena, Italy

  • Pratia Onkologia Katowice

    Katowice, Poland

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.